AFT Pharmaceuticals reports FY17 loss but sees return to profit on the horizon

Rebecca Howard
Tue, 23 May 2017

By Rebecca Howard May 24 (BusinessDesk) - AFT Pharmaceuticals, which manufactures the Maxigesic painkiller, reported a full-year loss in the year to March 31 but expects to significantly narrow those deficits this year and return to profitability in the 2018/19 period. The company reported a net loss of $18.4 million, or 19 cents per share, in the 12 months ended March 31, from a loss of $13.3 million, or 48 cents per share, in the prior year. Operating revenue rose to $69.2 million, meeting guidance and up from $64 million in the prior y...
Markets
MARKET CLOSE: NZ shares rise as optimism over covid drug buoys Asia
Dan Brunskill | Mon, 13 Jul 2020

New Zealand shares joined a rally across Asia, as upbeat investor sentiment spilled over from Wall Street's close on Friday on optimism over a late-stage trial for a hopeful covid-19 treatment.  Th...

Law & Regulation
SFO probes Labour Party on donations
Victoria Young | Mon, 13 Jul 2020

The Serious Fraud Office has confirmed a fifth investigation into electoral funding, stating today it is looking into donations to the Labour Party.The agency said the probe relates to donations made...

Markets
NZ dollar little changed as global shares defy worsening covid news
Jenny Ruth | Mon, 13 Jul 2020

The New Zealand dollar was little changed as traders awaited further trend-setting information and as rising share markets were offset by Florida reporting a US record for new covid infections. The...

The role of private equity in the wake of COVID-19

As local covid-19 restrictions ease, a new business cycle is beginning in New Zealand.